X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5088) 5088
Newsletter (27) 27
Magazine Article (22) 22
Book Chapter (7) 7
Newspaper Article (6) 6
Book Review (2) 2
Publication (2) 2
Dissertation (1) 1
Journal / eJournal (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4064) 4064
azithromycin (3143) 3143
anti-bacterial agents - therapeutic use (2786) 2786
azithromycin - therapeutic use (2513) 2513
female (2235) 2235
male (2216) 2216
adult (1416) 1416
infectious diseases (1238) 1238
pharmacology & pharmacy (1034) 1034
middle aged (1032) 1032
antibiotics (982) 982
microbiology (896) 896
treatment outcome (873) 873
animals (739) 739
adolescent (735) 735
child (702) 702
aged (657) 657
anti-bacterial agents - pharmacology (630) 630
azithromycin - administration & dosage (599) 599
infections (590) 590
anti-bacterial agents - administration & dosage (582) 582
immunology (569) 569
clarithromycin (553) 553
erythromycin (519) 519
infection (502) 502
child, preschool (493) 493
microbial sensitivity tests (490) 490
medicine, general & internal (484) 484
azithromycin - pharmacology (475) 475
children (464) 464
macrolides (444) 444
drug therapy (438) 438
health aspects (432) 432
research (423) 423
anti-bacterial agents - adverse effects (412) 412
care and treatment (404) 404
infant (393) 393
therapy (391) 391
drug therapy, combination (382) 382
azithromycin - adverse effects (371) 371
risk factors (360) 360
young adult (338) 338
drug resistance, bacterial (336) 336
respiratory system (329) 329
chlamydia infections - drug therapy (320) 320
pediatrics (317) 317
drug resistance (304) 304
prevalence (304) 304
analysis (302) 302
dosage and administration (302) 302
pneumonia (293) 293
efficacy (286) 286
clarithromycin - therapeutic use (285) 285
resistance (281) 281
abridged index medicus (275) 275
pharmacokinetics (275) 275
diagnosis (272) 272
antimicrobial resistance (271) 271
mice (269) 269
prevention (268) 268
macrolides - therapeutic use (265) 265
ciprofloxacin (262) 262
erythromycin - therapeutic use (262) 262
retrospective studies (262) 262
bacteria (257) 257
administration, oral (256) 256
antimicrobial agents (256) 256
double-blind method (255) 255
drug administration schedule (249) 249
disease (247) 247
research article (247) 247
doxycycline (246) 246
double-blind (244) 244
epidemiology (244) 244
doxycycline - therapeutic use (243) 243
inflammation (243) 243
prospective studies (240) 240
clinical trials (236) 236
time factors (233) 233
mortality (229) 229
medicine (222) 222
aged, 80 and over (214) 214
chlamydia trachomatis (213) 213
anti-bacterial agents - pharmacokinetics (212) 212
cystic fibrosis (212) 212
follow-up studies (211) 211
pregnancy (211) 211
susceptibility (209) 209
acute disease (205) 205
patients (199) 199
anti-infective agents - therapeutic use (196) 196
drug resistance in microorganisms (190) 190
internal medicine (190) 190
in-vitro (188) 188
macrolide (186) 186
studies (186) 186
community-acquired infections - drug therapy (182) 182
macrolide antibiotics (182) 182
management (181) 181
usage (178) 178
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4904) 4904
French (76) 76
Russian (51) 51
German (47) 47
Japanese (46) 46
Spanish (46) 46
Portuguese (35) 35
Chinese (22) 22
Italian (9) 9
Bulgarian (8) 8
Polish (6) 6
Croatian (5) 5
Danish (4) 4
Dutch (4) 4
Norwegian (4) 4
Finnish (2) 2
Hebrew (2) 2
Romanian (2) 2
Swedish (2) 2
Turkish (2) 2
Czech (1) 1
Icelandic (1) 1
Korean (1) 1
Persian (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, p. CD009764
Background There has been renewal of interest in the use of prophylactic antibiotics to reduce the frequency of exacerbations and improve quality of life in chronic obstructive pulmonary disease (COPD... 
Fluoroquinolones | Quinolines | Clarithromycin | Lungs & airways | Drug Administration Schedule | Pulmonary Disease, Chronic Obstructive | Azithromycin | Antibiotic Prophylaxis | Roxithromycin | Erythromycin | Moxifloxacin | Disease Progression | Randomized Controlled Trials as Topic | Trimethoprim, Sulfamethoxazole Drug Combination | Chronic obstructive pulmonary disease (stable) | Amoxicillin | Anti‐Bacterial Agents | Aza Compounds | Clavulanic Acid | Quality of Life | Chronic obstructive pulmonary disease, stable ‐ pharmacotherapy | Medicine General & Introductory Medical Sciences | Other medications | Azithromycin [therapeutic use] | STABLE COPD | Humans | AIRWAY INFLAMMATION | Quinolines [therapeutic use] | Anti-Bacterial Agents [therapeutic use] | MEDICINE, GENERAL & INTERNAL | DAILY PENICILLIN | Aza Compounds [therapeutic use] | TETRACYCLINE | Erythromycin [therapeutic use] | CHRONIC-BRONCHITIS | LONG-TERM AZITHROMYCIN | Antibiotic Prophylaxis [methods] | Pulmonary Disease, Chronic Obstructive [drug therapy] | ACUTE EXACERBATIONS | INDUCED SPUTUM | Clarithromycin [therapeutic use] | DOUBLE-BLIND | Aged | HEALTH-STATUS | Aza Compounds - therapeutic use | Anti-Bacterial Agents - therapeutic use | Anti-Bacterial Agents - adverse effects | Roxithromycin - adverse effects | Roxithromycin - therapeutic use | Antibiotic Prophylaxis - methods | Clarithromycin - therapeutic use | Trimethoprim, Sulfamethoxazole Drug Combination - adverse effects | Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use | Erythromycin - therapeutic use | Clavulanic Acid - adverse effects | Clavulanic Acid - therapeutic use | Azithromycin - adverse effects | Moxifloxacin - therapeutic use | Azithromycin - therapeutic use | Amoxicillin - therapeutic use | Amoxicillin - adverse effects | Quinolines - therapeutic use | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 2011, Volume 2019, Issue 5, p. CD006688
.... Objectives To compare the use of azithromycin alone or in combination with other antimalarial drugs with the use of alternative antimalarial drugs for treating uncomplicated malaria caused... 
Malaria, Falciparum | Malaria, Vivax | Artemether, Lumefantrine Drug Combination | Chloroquine | Azithromycin | Fluorenes | Antimalarials | Treating uncomplicated malaria | Infectious disease | Proguanil | Artesunate | Treatment Failure | Child health | Sulfadoxine | Drug Therapy, Combination | Mefloquine | Atovaquone | Malaria | Pyrimethamine | Ethanolamines | Treatment of uncomplicated falciparum malaria | Randomized Controlled Trials as Topic | Blood disorders | Treatment | Malaria: treating uncomplicated disease | Artemisinins | Medicine General & Introductory Medical Sciences | Drug Combinations | Single agent | SPOROZOITE-INDUCED INFECTIONS | VIVAX MALARIA | MEDICINE, GENERAL & INTERNAL | SULFADOXINE-PYRIMETHAMINE | ERYTHROMYCIN | DOUBLE-BLIND | ANTIMALARIAL ACTIVITY | RANDOMIZED-TRIAL | COMBINATION | PLASMODIUM-FALCIPARUM MALARIA | PREGNANCY | Pyrimethamine - therapeutic use | Malaria, Falciparum - drug therapy | Atovaquone - therapeutic use | Humans | Fluorenes - therapeutic use | Chloroquine - therapeutic use | Male | Antimalarials - therapeutic use | Proguanil - therapeutic use | Artemisinins - therapeutic use | Mefloquine - therapeutic use | Azithromycin - therapeutic use | Malaria, Vivax - drug therapy | Sulfadoxine - therapeutic use | Ethanolamines - therapeutic use | Female
Journal Article
Indian Journal of Medical Research, ISSN 0971-5916, 11/2017, Volume 146, Issue 5, pp. 622 - 628
Background & objectives: The in vitro assays for susceptibility of Plasmodium falciparum to antimalarial drugs are important tools for monitoring drug... 
Antimalarials | Plasmodium falciparum | Field isolates | In vitro culture | Antibiotics | Mizoram | MEDICINE, RESEARCH & EXPERIMENTAL | PYRIMETHAMINE | in vitro culture | antimalarials | MEFLOQUINE | IMMUNOLOGY | COMBINATION | FAILURE | THAILAND | MEDICINE, GENERAL & INTERNAL | MYANMAR | field isolates | ARTEMISININ RESISTANCE | MALARIA | QUININE | ARTESUNATE | Malaria, Falciparum - drug therapy | Atovaquone - therapeutic use | Doxycycline - therapeutic use | Humans | Fluorenes - therapeutic use | India - epidemiology | Chloroquine - therapeutic use | Antimalarials - therapeutic use | Plasmodium falciparum - drug effects | Chloroquine - analogs & derivatives | Anti-Bacterial Agents - therapeutic use | Malaria, Falciparum - parasitology | Quinine - therapeutic use | Artemisinins - therapeutic use | Mefloquine - therapeutic use | Azithromycin - therapeutic use | Malaria, Falciparum - epidemiology | Plasmodium falciparum - pathogenicity | Ethanolamines - therapeutic use | Quinolines - therapeutic use | Medical research | Microbial sensitivity tests | Patient outcomes | Medicine, Experimental | Dosage and administration | Research | Health aspects | Drugs | Scholarships & fellowships | Malaria | Erythrocytes | Parasites | Mutation | Original | Antibiotics - antimalarials - field isolates - in vitro culture - Mizoram - Plasmodium falciparum
Journal Article
PloS one, ISSN 1932-6203, 2015, Volume 10, Issue 9, p. e0138204
No effective drug and definitive "gold standard" treatment for Toxoplasma gondii (T. gondii) infection has been available so far, though some medicines have... 
DIAGNOSIS | IN-VITRO | TRANSMISSION | SULFADIAZINE | PYRIMETHAMINE | ENCEPHALITIS | MULTIDISCIPLINARY SCIENCES | PRENATAL TREATMENT | SPIRAMYCIN | CONGENITAL TOXOPLASMOSIS | ATOVAQUONE | Pyrimethamine - therapeutic use | Toxoplasmosis - drug therapy | Acquired Immunodeficiency Syndrome - transmission | Spiramycin - therapeutic use | Humans | Anti-Infective Agents - therapeutic use | Sulfadiazine - therapeutic use | Male | Treatment Outcome | Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use | Clindamycin - therapeutic use | Toxoplasmosis - parasitology | Pregnancy | Toxoplasmosis - complications | Azithromycin - therapeutic use | Female | Toxoplasma - drug effects | Acquired Immunodeficiency Syndrome - complications | Antiprotozoal Agents - therapeutic use | Drug Therapy, Combination | Infectious Disease Transmission, Vertical - prevention & control | Drugs | Medical research | Sulfadiazine | Encephalitis | Medicine, Experimental | Medicine, Chinese | Drug therapy | Health aspects | Therapy | Laboratories | Clindamycin | Azithromycin | Trimethoprim | Clinical trials | Systematic review | Biology | Infections | Parasites | Tropical diseases | Confidence intervals | Trimethoprim-sulfamethoxazole | Sulfamethoxazole | Acquired immune deficiency syndrome--AIDS | Search engines | Public health | Deoxyribonucleic acid--DNA | Protozoa | Pathogens | Spiramycin | Immunoglobulins | Congenital diseases | Statistical analysis | Pyrimethamine | Traditional Chinese medicine | Statistics | Conversion | Medicine | Scientific papers | Herbal medicine | Citation indexes | Disease transmission | Infectious diseases | Cysts | Sulfonamides | Womens health | Acquired immune deficiency syndrome | Deoxyribonucleic acid | AIDS | DNA
Journal Article
Clinical infectious diseases, ISSN 1537-6591, 12/2009, Volume 49, Issue 11, pp. 1703 - 1710
Journal Article
BMC infectious diseases, ISSN 1471-2334, 2018, Volume 18, Issue 1, pp. 609 - 8
Journal Article